Vistagen Therapeutics, Inc. (VTGN)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 03-31. Amounts in USD.

Revenue TTM

-900K 0 900K 1.8M 2.7M Q2 '22: 1.5M Q3 '22: 1.5M Q4 '22: 1.1M Q1 '23: 1.1M Q2 '23: -186.1K Q3 '23: -364K Q4 '23: -226.9K Q1 '24: -360K Q2 '24: 811K Q3 '24: 1M Q4 '24: 1.1M Q1 '25: 970K Q2 '25: 875K Q3 '25: 698K Q4 '25: 486K Q1 '26: 646K Q2 '26: 721K Q3 '26: 790K Q4 '26: 1.3M Q1 '27: 2.5M Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26 Q1 '27

Gross Profit TTM

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Operating Income TTM

-75M -50M -25M 0 25M 50M 75M Q2 '22: -32.1M Q3 '22: -37.3M Q4 '22: -47.8M Q1 '23: -59.8M Q2 '23: -64.5M Q3 '23: -63.7M Q4 '23: -59.3M Q1 '24: -46.5M Q2 '24: -35.8M Q3 '24: -33.9M Q4 '24: -33M Q1 '25: -38.2M Q2 '25: -45.6M Q3 '25: -52.8M Q4 '25: -56M Q1 '26: -59.6M Q2 '26: -65.5M Q3 '26: -69.9M Q4 '26: -72.1M Q1 '27: -69.7M Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26 Q1 '27

Net Income TTM

-75M -50M -25M 0 25M 50M 75M Q2 '22: -32M Q3 '22: -37.3M Q4 '22: -47.8M Q1 '23: -59.8M Q2 '23: -64.5M Q3 '23: -63.7M Q4 '23: -59.2M Q1 '24: -46.4M Q2 '24: -35.5M Q3 '24: -32.1M Q4 '24: -29.4M Q1 '25: -33.2M Q2 '25: -39.6M Q3 '25: -47.3M Q4 '25: -51.4M Q1 '26: -55.8M Q2 '26: -62.2M Q3 '26: -67M Q4 '26: -69.7M Q1 '27: -67.6M Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26 Q1 '27

Cost of Revenue TTM

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Operating Cash Flow TTM

-75M -50M -25M 0 25M 50M 75M Q2 '22: -27.9M Q3 '22: -34.9M Q4 '22: -45.3M Q1 '23: -55.1M Q2 '23: -59.9M Q3 '23: -57.8M Q4 '23: -49.7M Q1 '24: -41.6M Q2 '24: -31.5M Q3 '24: -26.3M Q4 '24: -25.8M Q1 '25: -28.8M Q2 '25: -33.5M Q3 '25: -39M Q4 '25: -42.1M Q1 '26: -50.1M Q2 '26: -52.9M Q3 '26: -60.3M Q4 '26: -66.4M Q1 '27: -62.3M Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26 Q1 '27

Free Cash Flow TTM

-75M -50M -25M 0 25M 50M 75M Q3 '22: -35.2M Q4 '22: -45.5M Q1 '23: -55.3M Q2 '23: -60.1M Q3 '23: -58M Q3 '22 Q4 '22 Q1 '23 Q2 '23 Q3 '23

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 70M 140M 210M Q2 '16: 1.6M Q3 '16: 1.8M Q1 '22: 189.9M Q2 '22: 193.2M Q3 '22: 202.3M Q4 '22: 6.9M Q1 '23: 6.9M Q2 '23: 6.9M Q3 '23: 6.9M Q4 '23: 7.2M Q1 '24: 7.3M Q2 '24: 10M Q3 '24: 29.4M Q1 '25: 30.6M Q2 '25: 30.6M Q3 '25: 30.7M Q1 '26: 31.9M Q2 '26: 35.7M Q3 '26: 42.2M Q1 '27: 43M Q3 '16 Q3 '22 Q2 '23 Q1 '24 Q1 '25 Q1 '26 Q1 '27

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-10.50 -7.00 -3.50 0.00 3.50 7.00 10.50 Q2 '22: -0.38 Q3 '22: -0.36 Q4 '22: -2.58 Q1 '23: -5.41 Q2 '23: -7.88 Q3 '23: -9.25 Q4 '23: -8.54 Q1 '24: -6.61 Q2 '24: -4.73 Q3 '24: -3.53 Q4 '24: -2.07 Q1 '25: -1.48 Q2 '25: -1.24 Q3 '25: -1.48 Q4 '25: -1.67 Q1 '26: -1.79 Q2 '26: -1.91 Q3 '26: -1.90 Q4 '26: -1.83 Q1 '27: -1.66 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26 Q1 '27

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.